Shares in Ultragenyx and Mereo BioPharma have plunged after their drug for osteogenesis imperfecta (OI) or brittle bone ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrew Newland, CEO of ANGLE, about why live cell liquid ...

The NHS has an extraordinary opportunity in 2026. Unified data, decision intelligence, and strong workforce capability can ...

Judge Lance Walker sided with the American Hospital Association (AHA) and other plaintiffs in the lawsuit, brought in a Maine ...

In 2026, we will see widespread adoption of AI tools that automate time-consuming administrative tasks: drafting clinical ...

Sanofi's last job before breaking up for the Christmas holiday? Putting the finishing touches on a $2.5 billion agreement to buy vaccine developer Dynavax. The French pharma major has started a $15.50 ...

Johnson & Johnson has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis (AD), after it ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Vinay Patel, an innovative pharmacist who's set out to ...

That scuppered Sanofi's plans for filing tolebrutinib in PPMS, and the FDA has now slammed the brakes on its efforts to get ...

To begin to close the equity gap in diabetes, we must commit to designing therapies that account for the practical realities ...

Bevacizumab has been sold as Avastin by originator Roche for many years and used by the NHS for various forms of cancer, with ...

In the latest of a flurry of announcements ahead of the holiday period, CMS has revealed a new, voluntary access programme that aims to broaden the use of GLP-1 agonist medicines for diabetes and ...